Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice

Experimental Eye Research

Volumn 85, Issue 3, 2007, Pages 323-327

  Lange, Clemens ^a   Ehlken, Christoph ^a   Martin, Gottfried ^a   Konzok, Kirstin ^a   Moscoso del Prado, Jaime ^b   Hansen, Lutz L ^a   Agostini, Hansjürgen T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Italfarmaco SA   (Spain)

Author keywords

5 amino 2 NMS; angiogenesis; fibroblast growth factor; heparin; inhibitor; oxygen induced retinopathy; retinal neovascularization

Indexed keywords

5 AMINO 2 NAPHTHALENESULFONATE; DEXTRAN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FLUORESCEIN; HEPARIN DERIVATIVE; OXYGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN BINDING; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; RETINOPATHY; SCORING SYSTEM;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FIBROBLAST GROWTH FACTORS; INJECTIONS; MICE; MICE, INBRED C57BL; NAPHTHALENESULFONATES; OXYGEN; RETINAL NEOVASCULARIZATION; VITREOUS BODY;

EID: 34547858198     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2007.05.007     Document Type: Article

References (35)

1. Agostini H.T., Boden K., Unsold A., Martin G., Hansen L., Fiedler U., Esser N., and Marme D. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr. Eye Res. 30 (2005) 249-257
2. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1 (1995) 1024-1028
3. Amin R., Puklin J.E., and Frank R.N. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 35 (1994) 3178-3188
4. Ashikari-Hada S., Habuchi H., Kariya Y., and Kimata K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J. Biol. Chem. 280 (2005) 31508-31515
5. Botta M., Manetti F., and Corelli F. Fibroblast growth factors and their inhibitors. Curr. Pharm. Des. 6 (2000) 1897-1924
6. Doggrell S.A. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert. Opin. Pharmacother. 6 (2005) 1421-1423
7. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16 (2005) 139-149
8. Fernandez-Tornero C., Lozano R.M., Redondo-Horcajo M., Gomez A.M., Lopez J.C., Quesada E., Uriel C., Valverde S., Cuevas P., Romero A., and Gimenez-Gallego G. Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. J. Biol. Chem. 278 (2003) 21774-21781
9. Higgins R.D., Yu K., Sanders R.J., Nandgaonkar B.N., Rotschild T., and Rifkin D.B. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr. Eye Res. 18 (1999) 20-27
10. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., and Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 51 (1991) 6180-6184
11. Itoh N., and Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20 (2004) 563-569
12. Jakobsson L., Kreuger J., Holmborn K., Lundin L., Eriksson I., Kjellen L., and Claesson-Welsh L. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev. Cell 10 (2006) 625-634
13. Jonca F., Ortega N., Gleizes P.E., Bertrand N., and Plouet J. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J. Biol. Chem. 272 (1997) 24203-24209
14. Kahn H.A., and Hiller R. Blindness caused by diabetic retinopathy. Am. J. Ophthalmol. 78 (1974) 58-67
15. Lee P., Wang C.C., and Adamis A.P. Ocular neovascularization: an epidemiologic review. (Review) (164 refs). Surv. Ophthalmol. 43 (1998) 245-269
16. Lozano R.M., Jimenez M., Santoro J., Rico M., and Gimenez-Gallego G. Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas. J. Mol. Biol. 281 (1998) 899-915
17. Maier P., Unsoeld A.S., Junker B., Martin G., Drevs J., Hansen L.L., and Agostini H.T. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch. Clin. Exp. Ophthalmol. 243 (2005) 593-600
18. Mandriota S.J., and Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 110 Pt 18 (1997) 2293-2302
19. Matsushima M., Ogata N., Takada Y., Tobe T., Yamada H., Takahashi K., and Uyama M. FGF receptor 1 expression in experimental choroidal neovascularization. Jpn. J. Ophthalmol. 40 (1996) 329-338
20. Michels S., and Rosenfeld P.J. Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis. Klin. Monatsbl. Augenheilkd. 222 (2005) 480-484
21. Miyashiro M., Ogata N., Takahashi K., Matsushima M., Yamamoto C., Yamada H., and Uyama M. Expression of basic fibroblast growth factor and its receptor mRNA in retinal tissue following ischemic injury in the rat. Graefes Arch. Clin. Exp. Ophthalmol. 236 (1998) 295-300
22. Ozaki H., Okamoto N., Ortega S., Chang M., Ozaki K., Sadda S., Vinores M.A., Derevjanik N., Zack D.J., Basilico C., and Campochiaro P.A. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. (see comments). Comment in: Am J Pathol 1998 Sep;153(3):665-70. Am. J. Pathol. 153 (1998) 757-765
23. Powers C.J., McLeskey S.W., and Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 7 (2000) 165-197
24. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., and Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16 (2005) 159-178
25. Presta M., Leali D., Stabile H., Ronca R., Camozzi M., Coco L., Moroni E., Liekens S., and Rusnati M. Heparin derivatives as angiogenesis inhibitors. Curr. Pharm. Des. 9 (2003) 553-566
26. Robinson C.J., Mulloy B., Gallagher J.T., and Stringer S.E. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J. Biol. Chem. 281 (2006) 1731-1740
27. Rousseau B., Dubayle D., Sennlaub F., Jeanny J.C., Costet P., Bikfalvi A., and Javerzat S. Neural and angiogenic defects in eyes of transgenic mice expressing a dominant-negative FGF receptor in the pigmented cells. Exp. Eye Res. 71 (2000) 395-404
28. Rousseau B., Larrieu-Lahargue F., Bikfalvi A., and Javerzat S. Involvement of fibroblast growth factors in choroidal angiogenesis and retinal vascularization. Exp. Eye Res. 77 (2003) 147-156
29. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., and D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35 (1994) 101-111
30. Tobe T., Ortega S., Luna J.D., Ozaki H., Okamoto N., Derevjanik N.L., Vinores S.A., Basilico C., and Campochiaro P.A. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 153 (1998) 1641-1646
31. Unsoeld A.S., Junker B., Mazitschek R., Martin G., Hansen L.L., Giannis A., and Agostini H.T. Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice. Mol. Vis. 10 (2004) 468-475
32. Valter K., Maslim J., Bowers F., and Stone J. Photoreceptor dystrophy in the RCS rat: roles of oxygen, debris, and bFGF. Invest. Ophthalmol. Vis. Sci. 39 (1998) 2427-2442
33. Yamada H., Yamada E., Ando A., Esumi N., Bora N., Saikia J., Sung C.H., Zack D.J., and Campochiaro P.A. Fibroblast growth factor-2 decreases hyperoxia-induced photoreceptor cell death in mice. Am. J. Pathol. 159 (2001) 1113-1120
34. Yamada H., Yamada E., Hackett S.F., Ozaki H., Okamoto N., and Campochiaro P.A. Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina. J. Cell. Physiol. 179 (1999) 149-156
35. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., and Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281 (2006) 15694-15700